Interference between copper transport systems and platinum drugs

Semin Cancer Biol. 2021 Nov:76:173-188. doi: 10.1016/j.semcancer.2021.05.023. Epub 2021 May 29.

Abstract

Cisplatin, or cis-diamminedichloridoplatinum(II) cis-[PtCl2(NH3)2], is a platinum-based anticancer drug largely used for the treatment of various types of cancers, including testicular, ovarian and colorectal carcinomas, sarcomas, and lymphomas. Together with other platinum-based drugs, cisplatin triggers malignant cell death by binding to nuclear DNA, which appears to be the ultimate target. In addition to passive diffusion across the cell membrane, other transport systems, including endocytosis and some active or facilitated transport mechanisms, are currently proposed to play a pivotal role in the uptake of platinum-based drugs. In this review, an updated view of the current literature regarding the intracellular transport and processing of cisplatin will be presented, with special emphasis on the plasma membrane copper permease CTR1, the Cu-transporting ATPases, ATP7A and ATP7B, located in the trans-Golgi network, and the soluble copper chaperone ATOX1. Their role in eliciting cisplatin efficacy and their exploitation as pharmacological targets will be addressed.

Keywords: ATOX1; ATP7A; ATP7B; CTR1; Cancer; Cisplatin; Cisplatin resistance; Copper homeostasis; Copper transporters; Platinum trafficking; Pt-interference with copper metabolism; Sensitization therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism*
  • Cisplatin / metabolism*
  • Copper / metabolism*
  • Copper Transport Proteins / metabolism*
  • Drug Resistance, Neoplasm / physiology
  • Humans

Substances

  • Antineoplastic Agents
  • Copper Transport Proteins
  • Copper
  • Cisplatin